Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zero Candida TechnologiesTSXV:ZCT 14 Debt-to-Equity is 0.02 as of Dec. 2025. GuruFocus rates TSXV:ZCT with a GF Score™ of 14/100. The stock has 1 warning sign investors should review. Among 702 Medical Devices & Instruments companies, Zero Candida Technologies ranks better than 92.59% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Zero Candida Technologies's Debt-to-Equity or its related term are showing as below:
TSXV:ZCT'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.33 Med: -0.26 Max: 0.02
Current: 0.02
During the past 3 years, the highest Debt-to-Equity Ratio of Zero Candida Technologies was 0.02. The lowest was -0.33. And the median was -0.26.
TSXV:ZCT's Debt-to-Equity is ranked better than 92.59% of 702
companies
in the Medical Devices & Instruments industry
Industry Median: 0.22
vs TSXV:ZCT: 0.02
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Zero Candida Technologies Debt-to-Equity Related Terms
Zero Candida Technologies Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSXV:ZCT vs ABT, SYK, MDT: Debt-to-Equity Comparison
For the Medical Devices subindustry, Zero Candida Technologies's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zero Candida Technologies Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Zero Candida Technologies's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Zero Candida Technologies's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zero Candida Technologies (TSXV:ZCT) has a Debt-to-Equity of 0.02 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Zero Candida Technologies and its competitors. According to the industry distribution chart, Zero Candida Technologies ranks #52 out of 702 companies in the Medical Devices & Instruments industry, placing it in the top 7.4%.
Is Zero Candida Technologies' Debt-to-Equity too high?
Zero Candida Technologies' current Debt-to-Equity is 0.02. The Medical Devices & Instruments industry median Debt-to-Equity is 0.22. Zero Candida Technologies' value of 0.02 is 90.9% below this industry median. Based on the distribution chart, Zero Candida Technologies ranks #52 out of 702 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Zero Candida Technologies has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Zero Candida Technologies' Debt-to-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Zero Candida Technologies ranks #52 out of 702 companies for Debt-to-Equity. This places Zero Candida Technologies in the top 7% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.22. Zero Candida Technologies' value of 0.02 is 90.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.22, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zero Candida Technologies's current Debt-to-Equity of 0.02 is 90.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Zero Candida Technologies and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zero Candida Technologies's current Debt-to-Equity is 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zero Candida Technologies stock overvalued right now?
Zero Candida Technologies (TSXV:ZCT) has a current Debt-to-Equity of 0.02. The current Debt-to-Equity is 0.02 and 90.9% below the Medical Devices & Instruments industry median of 0.22. Zero Candida Technologies' overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Zero Candida Technologies (TSXV:ZCT), the current Debt-to-Equity is 0.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Zero Candida Technologies Inc is engaged in providing female healthcare solutions. The company technology uses a controlled Blue Light to destroy the fungus at record speed and without side effects. It focused on developing and commercializing several patents and patent applications concerning an AI smart tampon-like device, designed to treat Candidiasis and transfer medical information via Wi-Fi to the doctor.
14GF Score
Get the complete analysis for TSXV:ZCT
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:ZCT has been successfully added to your 
